| Oct 7 |
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
|
| Oct 4 |
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
|
| Oct 3 |
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
|
| Sep 26 |
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
|
| Sep 5 |
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
|
| Aug 29 |
Ultragenyx to Participate in Investor Conferences in September
|
| Aug 22 |
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
|
| Aug 6 |
3 Genomics Stocks That May Transform Personalized Medicine
|
| Aug 2 |
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript
|
| Aug 2 |
Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
|
